决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells.
通过利用一种双用途转化策略——直接的癌细胞靶向细胞毒性和增强的CAR T细胞浸润——sIRE能够减轻肿瘤负荷,同时保持并增强CAR T细胞功能。
实体瘤细胞治疗中一个反复出现的挑战是过继转移 T 细胞的肿瘤浸润不良。我们之前表明,亚消融剂量的肿瘤靶向放疗可产生趋化因子梯度,促进实体瘤中嵌合抗原受体 (CAR) T 细胞的浸润、增殖和记忆表型。然而,放疗对浸润的 CAR T 细胞具有细胞毒性,限制了其重复使用。
我们假设不可逆电穿孔能够产生趋化因子梯度,从而促进 CAR T 细胞浸润至实体瘤,并且针对选择性癌细胞裂解(由此保护浸润的 CAR T 细胞)进行调节的选择性不可逆电穿孔(sIRE)可以重复使用。利用实验筛选和模拟模型,我们优化了 sIRE 参数,以杀死癌细胞同时保护 T 细胞。
利用3D肿瘤模拟物和恶性胸膜间皮瘤小鼠模型,我们证实了重复sIRE的治疗获益。受sIRE损伤的癌细胞分泌趋化因子,促进全身给药的CAR T细胞迁移和肿瘤浸润,并在肿瘤再挑战模型中促进持久免疫。
PURPOSE: One recurring challenge in cell therapy for solid tumors is poor tumor infiltration of adoptively transferred T cells. We previously showed that a subablative dose of tumor-targeted radiation generates a chemokine gradient that promotes infiltration, proliferation, and a memory phenotype of chimeric antigen receptor (CAR) T cells in solid tumors. However, radiation is cytotoxic to infiltrating CAR T cells, limiting its repeated use. EXPERIMENTAL DESIGN: We hypothesized that irreversible electroporation could generate a chemokine gradient that promotes CAR T-cell infiltration into solid tumors and that selective irreversible electroporation (sIRE) tuned for selective cancer cell lysis (thus sparing infiltrating CAR T cells) can be used in a repeated fashion. Using experimental screening and simulation models, we optimized sIRE parameters to kill cancer cells while sparing T cells. RESULTS: Using 3D tumor mimics and mouse models of malignant pleural mesothelioma, we confirmed the therapeutic benefit of repeated sIRE. Chemokine secretion by cancer cells injured by sIRE promoted migration and tumor infiltration of systemically administered CAR T cells and facilitated sustained immunity in a tumor-rechallenge model. CONCLUSIONS: By leveraging a dual-purpose translational strategy-through direct cancer cell-targeted cytotoxicity and augmented CAR T-cell infiltration-sIRE can reduce cancer burden while preserving and enhancing CAR T-cell function.
MEMBER ACCOUNT
登录成功会直接打开下一页。